I have accumulated more than twenty years of experience in biotechnology. I started as a Research Associate at the National Cancer Institute in Mexico, where I took part in Phase I/II clinical studies of an epigenetic drug (Transkrip) that I helped develop. Following that, I worked as a project manager at Alpharma Laboratories and later co-founded Global BioTherapeutics USA Inc. As the CSO, I co-invented two medical devices and viral vectors. Currently, I am the CEO and founder of Triovance Holding, LLC, a regenerative medicine company focusing on gene and cell therapies for type 2 diabetes and its complications. I hold patents for 5 PCT inventions and have authored multiple papers published in scientific journals. Furthermore, I am an active member of the American Society of Gene and Cell Therapy. I am eagerly looking forward to working with the NIH to advance my TRV-01 wound dressing through the SBIR funding mechanism. This product aims to treat diabetic foot ulcers and has shown promising results in preliminary animal and human research. Every place where I have worked has contributed to the new development for Triovance in an important way. For example, at the National Cancer Institute, I learned how to control angiogenesis. At Global BioTherapeutics, I gained insights on how to control a diabetic microenvironment, and at Alpharma, I learned how to drive products to the market. Each part of your life, whether good or bad, contributes to preparing a company to be successfu
I have accumulated more than twenty years of experience in biotechnology. I started as a Research Associate at the National Cancer Institute in Mexico, where I took part in Phase I/II clinical studies of an epigenetic drug (Transkrip) that I helped develop. Following that, I worked as a project manager at Alpharma Laboratories and later co-founded Global BioTherapeutics USA Inc. As the CSO, I co-invented two medical devices and viral vectors. Currently, I am the CEO and founder of Triovance Holding, LLC, a regenerative medicine company focusing on gene and cell therapies for type 2 diabetes and its complications. I hold patents for 5 PCT inventions and have authored multiple papers published in scientific journals. Furthermore, I am an active member of the American Society of Gene and Cell Therapy. I am eagerly looking forward to working with the NIH to advance my TRV-01 wound dressing through the SBIR funding mechanism. This product aims to treat diabetic foot ulcers and has shown promising results in preliminary animal and human research. Every place where I have worked has contributed to the new development for Triovance in an important way. For example, at the National Cancer Institute, I learned how to control angiogenesis. At Global BioTherapeutics, I gained insights on how to control a diabetic microenvironment, and at Alpharma, I learned how to drive products to the market. Each part of your life, whether good or bad, contributes to preparing a company to be successfu